Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 324-325

  Lee, J H ^a   Lee, J M ^a   Lim, K H ^a   Kim, J K ^a   Ahn, S K ^a   Bang, Y J ^b   Hong, C I ^a  

^a Chong Kun Dang Research Institute   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

7 [2 (N ISOPROPYLAMINO)ETHYL]CAMPTOTHECIN; BELOTECAN; CAMPTOTHECIN DERIVATIVE; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG TOLERABILITY; HUMAN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; VOMITING;

EID: 0034517554     PISSN: 00778923     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1749-6632.2000.tb07055.x     Document Type: Article

References (4)

1. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent topoisomerase I inhibitor
2. Antitumor activities of CKD602, a novel camptothecin derivative
3. Toxicity, pharmacokinetics and cell-killing kinetics of CKD-602, a novel camptothecin agent